PRESS RELEASE
NLC Health Ventures introduces new venture transforming cardiovascular care NLC Health Ventures launches Revadix, an innovative biotech venture focused on improving the lives of millions of patients with atrial fibrillation (AF). Unlike current treatments that mostly improve symptoms but are not curative, Revadix is developing a new therapy that targets specifically dysfunctional signalling, thus restoring […]